Light Chain Amyloid Fibrils Cause Metabolic Dysfunction in Human Cardiomyocytes.
Light chain (AL) amyloidosis is the most common form of systemic amyloid disease, and cardiomyopathy is a dire consequence, resulting in an extremely poor prognosis. AL is characterized by the production of monoclonal free light chains that deposit as amyloid fibrils principally in the heart, liver,...
Main Authors: | Helen P McWilliams-Koeppen, James S Foster, Nicole Hackenbrack, Marina Ramirez-Alvarado, Dallas Donohoe, Angela Williams, Sallie Macy, Craig Wooliver, Dale Wortham, Jennifer Morrell-Falvey, Carmen M Foster, Stephen J Kennel, Jonathan S Wall |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4579077?pdf=render |
Similar Items
-
AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils.
by: Jonathan S Wall, et al.
Published: (2012-01-01) -
Preclinical Validation of the Heparin-Reactive Peptide p5+14 as a Molecular Imaging Agent for Visceral Amyloidosis
by: Jonathan S. Wall, et al.
Published: (2015-04-01) -
Evaluation of the effect of d-amino acid incorporation into amyloid-reactive peptides
by: Emily B. Martin, et al.
Published: (2017-12-01) -
Development and characterization of a prototypic pan-amyloid clearing agent – a novel murine peptide-immunoglobulin fusion
by: James S. Foster, et al.
Published: (2023-10-01) -
Clinical Confirmation of Pan-Amyloid Reactivity of Radioiodinated Peptide <sup>124</sup>I-p5+14 (AT-01) in Patients with Diverse Types of Systemic Amyloidosis Demonstrated by PET/CT Imaging
by: Emily B. Martin, et al.
Published: (2023-04-01)